Aflac Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $18.1B-4.5% YoYTTM through 30 Jun 2026
Net Income $4.9B-10.7% YoYTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | 32.0% |
| Net Margin | 26.9% |
Returns
16.0%ROE
4.2%ROA
14.9%ROIC
Balance Sheet Health
Debt / Equity0.28x
Net Debt$2.3B
Cash & Equivalents$6.1B
Quality Metrics
Piotroski F-Score3 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $17.2B
Diluted EPS$9.27TTMFY2025: $6.82
Dividend
$1.22Per share, FY20261.06%Yield-1.6%5-yr growth
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Aflac Japan | $9.4B | -3.1% | View detailsFor 2026, Aflac Japan is expected to generate a benefit ratio in the range of 60% to 63% and an expense ratio in the range of 20% to 23% |
| Aflac U.S. | $6.9B | +2.4% | View detailsFor 2026, Aflac U.S. is expected to generate a benefit ratio in the range of 48% to 52% and an expense ratio in the range of 36% to 39% |
| Other Segments | $1.3B | +26.8% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.